An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.

Deparment of Biostatistics Lysarc Lyon France

Hematology Department Centre Hospitalier De La Roche Sur Yon France

Hematology Department Centre Hospitalier Pontchaillou Rennes France

Hematology Department CHU De Reims Reims France

Hematology Department Chulalongkorn University Bangkok Thailand

Hematology Department Cliniques Universitaires UCL Saint Luc Brussels Belgium

Hematology Department Concord Hospital Concord NSW Australia

Hematology Department Hôpital Lyon Sud and Université Claude Bernard Pierre Bénite France

Hematology Department Hospital Son Llàtzer Palma De Mallorca Spain

Hematology Department Institut Gustave Roussy Villejuif France

Hematology Department Institut Paoli Calmettes Marseille France

Hematology Department Peter MacCallum Cancer Centre and University of Melbourne Melbourne VIC Australia

Hematology Department Polyclinique Bordeaux Nord Aquitaine Bordeaux France

Hematology Department Portuguese Institute of Oncology Lisbon Portugal

Hematology Department University Hospital Hradec Kràlové Prague Czech Republic

References provided by Crossref.org